Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

Sponsor
Fudan University
Study ID
NCT05303038
Phase
PHASE2
Status
Unknown

Conditions

  • Metastatic Breast Cancer in the Liver

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Cryoablation Combined with Tirelizumab and Bevacizumab — COMBINATION_PRODUCT
    Cryoablation of 1-2 typical metastatic lesions will be performed on D1 under general anesthesia and ultrasound guidance for two cycles. 200mg Tirelizumab ( IV Q3W) + Bevacizumab 7.5mg/kg ( IV Q3W) will be administered at D14 after cryoablation.

Study Details

This is a Phase II, open-label study evaluating the efficacy and safety of Cryoablation combined with Tirelizumab and Bevacizumab in liver metastatic triple-negative breast cancer patients failed by multiline therapy.

Key Dates

First listed
Mar 31, 2022
Start date
May 1, 2022
Status verified
Apr 2022
Primary completion
Apr 1, 2024
Completion
Apr 1, 2024

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: cryoablation combined with tirelizumab + Bevacizumab

Primary Outcome Measure

ORR [ Time Frame: Up to 12 months ]

Central Contacts

Related Studies